Novartis(US:NVS) Jing Ji Ri Bao·2025-11-04 22:49Core Insights - China is the second-largest and strategically important market for Novartis, with over 40 innovative drugs and indications approved since its debut at the China International Import Expo in 2018 [1][3] - Novartis has accelerated its investment in the Chinese market, with over 100 innovative drugs and new indications approved to date, achieving 100% synchronization with global new drug and indication development since 2022 [1] - A significant investment of 600 million RMB is being made by Novartis to establish a radiopharmaceutical production base in Haiyan, Zhejiang, expected to be operational by the end of 2026, demonstrating long-term confidence in the Chinese market [1] - The China International Import Expo serves as a platform for Novartis to deepen its understanding of China's medical innovation landscape and strengthen collaborations, showcasing nearly 20 innovative products across key therapeutic areas [1][3] - Novartis aims to become the most valuable and trusted healthcare partner in China, committing to contribute to the "Healthy China 2030" strategic goals through deeper integration into the local medical innovation ecosystem [1]